FTCM
APGE icon

First Trust Capital Management’s Apogee Therapeutics APGE Stock Holding History

First Trust Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83M Buy
+625,182
New +$56.3M 4.83% 5

Other funds holding APGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

First Trust Capital Management's APGE Position: Q2 2026 in Review

First Trust Capital Management opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 625,182 shares worth $83M. The stake represents 4.83% of the portfolio and ranks #5 among its holdings.

173 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • First Trust Capital Management held 625,182 shares of Apogee Therapeutics worth $83M as of Q2 2026.
  • Apogee Therapeutics was a new First Trust Capital Management position in Q2 2026.
  • Apogee Therapeutics made up 4.83% of First Trust Capital Management's portfolio in Q2 2026, its #5 holding.
  • 173 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on First Trust Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.